Assessment of Capsule Endoscopy Scoring Index (CESI), Harvey-Bradshaw Index (HBI) and Biological Markers in Small Bowel Crohn's Disease (SBCD)

Launched by SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · Mar 14, 2012

Keywords

ClinConnect Summary

Parameters CESI To calculate the CESI, the small bowel was divided into three tertiles. The degree of disease involvement in each tertile was determined by assessing three parameters: villous edema, ulceration, and stenosis. Endoscopic remission was defined as CESI of \<135. Mild inflammation was defined as CESI of 135-790, and moderate-severe inflammation as ≥790.

HBI HBI was used to assess the clinical disease activity. Patients with HBI \>4 were considered to have clinically active disease.\[7\]

Blood analysis At the time of CE, patients provided a blood sample for measurement of hemog...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients with known SBCD or newly diagnosed SBCD
• • those patients for whom complete CE examination (in which the capsule
• • reached the cecum within the CE test time) was achieved were retained for study
• Exclusion Criteria:
• • incomplete CE examination
• • infectious enterocolitis
• • symptoms related to perianal penetrating disease
• • gastrointestinal cancer
• • ulcerative colitis
• • indeterminate colitis
• • history of extensive small bowel resection
• • known CD of the upper gastrointestinal tract or colon
• • intake of non-steroidal anti-inflammatory drugs (NSAIDs) (more than two tablets per week)
• • pregnancy